Literature DB >> 16700739

Pilocarpine for the treatment of salivary glands' impairment caused by radioiodine therapy for thyroid cancer.

D J Aframian1, M Helcer, D Livni, A Markitziu.   

Abstract

OBJECTIVES: To study the effect of single-dose pilocarpine hydrochloride 5 mg on the whole unstimulated and stimulated salivary flow in patients suffering from thyroid cancer treated with radioiodine therapy, and to investigate the changes in vital signs during the treatment. SUBJECTS AND METHODS: Five such patients were referred with complaints of dry mouth, rampant caries, and pain in the parotid gland region or history of chronic recurrent suppurative sialodenitis. A single dose of 5 mg pilocarpine hydrochloride was administered to each patient and blood pressure, heart rate, body temperature and salivary secretion rate were monitored at 1, 2 and 3 h.
RESULTS: A significant elevation of unstimulated and stimulated saliva flow rate was observed in four patients without significant alteration of the monitored vital signs.
CONCLUSIONS: Treatment with pilocarpine hydrochloride may be beneficial in the case of impaired salivary function in patients treated with radioiodine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16700739     DOI: 10.1111/j.1601-0825.2005.01195.x

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  9 in total

Review 1.  A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact.

Authors:  S B Jensen; A M L Pedersen; A Vissink; E Andersen; C G Brown; A N Davies; J Dutilh; J S Fulton; L Jankovic; N N F Lopes; A L S Mello; L V Muniz; C A Murdoch-Kinch; R G Nair; J J Napeñas; A Nogueira-Rodrigues; D Saunders; B Stirling; I von Bültzingslöwen; D S Weikel; L S Elting; F K L Spijkervet; M T Brennan
Journal:  Support Care Cancer       Date:  2010-03-25       Impact factor: 3.603

Review 2.  RETRACTED ARTICLE: Radiation sialadenitis induced by high-dose radioactive iodine therapy.

Authors:  Shin Young Jeong; Jaetae Lee
Journal:  Nucl Med Mol Imaging       Date:  2010-04-21

3.  A pretest-posttest pilot study for the development and preliminary validation of a tool for the clinical assessment of radioiodine induced sialadenitis.

Authors:  Andri Christou; Evridiki Papastavrou; Anastasios Merkouris; Andreas Charalambous
Journal:  SAGE Open Med       Date:  2021-09-01

4.  Prevention of salivary gland dysfunction in patients treated with radioiodine for differentiated thyroid cancer: A systematic review of randomized controlled trials.

Authors:  Arunrat Auttara-Atthakorn; Jaruwan Sungmala; Thunyarat Anothaisintawee; Sirimon Reutrakul; Chutintorn Sriphrapradang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-29       Impact factor: 6.055

5.  Reduced Endocannabinoid Tone in Saliva of Chronic Orofacial Pain Patients.

Authors:  Yaron Haviv; Olga Georgiev; Tal Gaver-Bracha; Sharleen Hamad; Alina Nemirovski; Rivka Hadar; Yair Sharav; Doron J Aframian; Yariv Brotman; Joseph Tam
Journal:  Molecules       Date:  2022-07-21       Impact factor: 4.927

Review 6.  Clinical Studies of Nonpharmacological Methods to Minimize Salivary Gland Damage after Radioiodine Therapy of Differentiated Thyroid Carcinoma: Systematic Review.

Authors:  Andri Christou; Evridiki Papastavrou; Anastasios Merkouris; Savvas Frangos; Panayiota Tamana; Andreas Charalambous
Journal:  Evid Based Complement Alternat Med       Date:  2016-06-30       Impact factor: 2.629

Review 7.  Seeking Optimal Management for Radioactive Iodine Therapy-induced Adverse Effects.

Authors:  Andreas Charalambous
Journal:  Asia Pac J Oncol Nurs       Date:  2017 Oct-Dec

Review 8.  Common oral complications of head and neck cancer radiation therapy: mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease, and osteoradionecrosis.

Authors:  Herve Y Sroussi; Joel B Epstein; Rene-Jean Bensadoun; Deborah P Saunders; Rajesh V Lalla; Cesar A Migliorati; Natalie Heaivilin; Zachary S Zumsteg
Journal:  Cancer Med       Date:  2017-10-25       Impact factor: 4.452

9.  Pilocarpine used to treat xerostomia in patients submitted to radioactive iodine therapy: a pilot study.

Authors:  Juliana Pereira Almeida; Luiz Paulo Kowalski
Journal:  Braz J Otorhinolaryngol       Date:  2010 Sep-Oct
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.